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Editorial – Special Issue of the 7th European Workshop on Lipid Mediators 
The Seventh European Workshop on Lipid Mediators (7EWLM) was held at Université 
catholique de Louvain in Brussels, Belgium September 12-14, 2018. The aim of the workshop was 
to bring together those researchers and students interested in the field of bioactive lipid mediators. 
The seventh edition of this biennial workshop was organized by Giulio Muccioli, Mireille Al 
Houayek, Gerard Bannenberg, Joan Clària, Per-Johan Jakobsson, Xavier Norel, Nils Helge Schebb 
and Chengcan Yao. The three-day event provided a good opportunity for participants to present their 
work, and enjoy a variety of presentations by experts, a session for young scientists, an educational 
session on analytical chemistry of lipid mediators, and poster sessions (see full program and download 
the abstract book at https://workshop-lipid.eu//7EWLM/index.php?cat=Program). More than 200 
scientists from across and outside Europe attended the workshop on the impressive campus of 
Université catholique de Louvain located in -Brussels. The workshop placed special focus on the 
following themes: i) lipid mediator receptors and signalling, ii) lipid mediators in immune and 
inflammatory responses, iii) lipid mediators in vascular and metabolic diseases, iv) 
endocannabinoids, v) lipidomics and advances in fatty acids and their derivatives. 
Here, we present to you this Special Issue of Prostaglandins and Other Lipid Mediators with 
a total of fourteen publications equally comprised of reviews and original publications by speakers 
who presented at the 7EWLM. This Special Issue is neither a systematic nor comprehensive review 
of all the topics and presentations delivered at the 7EWLM, but rather highlights the voluntary 
contributions of the participating scientists and their research colleagues. 
In the first of the six reviews in this special issue, the organiser of the former EWLM in 
Frankfurt, Steinhilber and colleagues provide an overview of the cellular functions of 5-lipoxygenase 
(5-LOX). This paper summarizes the factors that regulate 5-LOX expression and addresses the 
biological functions of 5-LOX beyond its largely recognized role in leukotriene and SPM formation, 
especially its interaction with p53 and the regulation of developmental pathways. Balvers, Albada 
and colleagues reviewed recent progress on the roles of omega-3 long-chain polyunsaturated fatty 
acid (n-3 LCPUFA)-derived fatty acid derivatives and their oxygenated metabolites in the modulation 
of inflammation. It is suggested that n-3 LCPUFA intake changes circulating LCPUFA, oxylipin and 
endocannabinoid profiles and that n-3 LCPUFA-derived metabolites, such as the endocannabinoid-
like compounds eicosapentaenoyl ethanolamide (EPEA) and docosahexaenoyl ethanolamide 
(DHEA), have higher anti-inflammatory and anti-proliferative potential than their precursors. The 
authors also discuss the emergent need for development of chemical probes to study n-3 LCPUFA 
metabolism. The next comprehensive review focusses on oxysterols. Oxysterols are located in the 
pathway from cholesterol to bile acids and are now considered as lipid mediators of great interest. 
Griffith and Wang  summarize the mechanisms for the formation of the main oxysterols. Disruption 
of these metabolic pathways is responsible for several diseases such as Lysosomal Storage Disorders 
that are also discussed by the authors in the context of oxysterol metabolism. Weigert and colleagues, 
discuss in their review that cancer associated fibroblast (CAF) are promoting tumour progression, an 
effect partly due to their ability to produce PGE2. However, these authors show an opposition with 
the protective effect of PGE2 in most fibrosis models. PGE2 is a pro-tumour lipid mediator whilst at 
the same time PGE2 can attenuate the CAF phenotype in a homeostatic manner. A potential 
pharmacological intervention in cancer, but also cardiovascular and other diseases, are inhibitors of 
microsomal prostaglandin E synthetase 1. Jakobsson and colleagues assessed recent results on 
development of mPGES-1 inhibitors in preclinical models and their future clinical applications. The 
integration of fatty acids and lipid mediators in the membrane requires their activation by coenzyme 
A. In the next review, Kuwata and Hara summarize and discuss the current knowledge on acyl 
synthetase long-chain isoform (ACSL) 4 in the context of PUFA, and especially arachidonic acid, 
metabolism.  
 
The first original research publications focus also on the multiple roles of PGE2 in the 
regulation of pathological states. In cancer, inhibition of tyrosine kinase receptors (like epidermal 
growth factor receptor (EGFR)) is an efficient treatment, but resistance is a challenge. Morbidelli, 
Donnini and Coworkers found an increased mPGES-1/PGE2 pathway in gefitinib (EGFR inhibitor) 
-resistant non-small cell lung cancer (NSCLC). PGE2 amplifies the pro-tumorigenic properties in 
these human NSCLC cells resistant to gefinitib. This effect is associated with acquisition of 
mesenchymal and stem-like properties and nuclear EGFR translocation. One mPGES-1 inhibitor 
(MF63) is able to overcome acquired resistance to gefitinib in NSCLC cell lines. Therefore, mPGES-
1 inhibitors as well as cyclooxygenase-2 inhibitors are increasingly suggested to be therapeutic 
approaches for treating aggressive and resistant lung cancers. 
Using prostanoids as biomarkers, Pawelzik and coworkers studied the effect of obesity on urinary 
prostanoid levels. In their paper, they report that tetranor-PGDM and tetranor-PGEM are the two 
major urinary prostanoid metabolites in the obese subjects studied. They also found that these two 
mediators’ urinary levels associate with metabolic parameters. Norel and coworkers investigate the 
interaction between PGI2 and ET-1 pathways in vascular smooth muscle from pulmonary 
hypertension patients: Prostacyclin analogues and endothelin-1 receptor antagonists are used for 
treating pulmonary hypertension. In this study, the researchers investigate whether the combination 
of a PGI2 analogue and an endothelin-1 receptor antagonists may be more effective than each 
treatment alone to treat pulmonary hypertension Group-III patients. They found that antagonizing ex 
vivo the endothelin receptor type B increases endothelin-1 production in pulmonary arteries and 
parenchyma. Moreover, the combination of an antagonist of the ETA receptor with iloprost results in 
a larger inhibition of human pulmonary artery smooth muscle cell proliferation than each drug alone. 
Fowler and coworkers focuses on the endocannabinoid system in the context of neuroblastoma. They 
used a human neuroblastoma cell line, i.e. SH-SY5Y cells, to investigate the expression of the genes 
coding for the enzymes involved in the synthesis and catabolism of endocannabinoids. When 
considering the important role of 2-arachidonoylgleycerol in the CNS, an interesting finding was the 
relatively low expression and enzymatic activity of monoacylglycerol lipase (MAGL) compared to 
α/β hydrolase domain 6 (ABHD6) in these cells.  
Two papers in this Special Issue focus on the analytical chemical methods necessary to quantify lipid 
mediators in biological samples. Garscha and coworkers developed a new analytical approach for 
the identification and quantification of glutathione (GSH) conjugates of oxygenated polyunsaturated 
fatty acids. These lipid mediators comprise pro-inflammatory conjugates such as the cysteinyl 
leukotrienes, eoxins and five-oxo-GSH conjugate (FOG7) derived from arachidonic acid, as well as 
conjugates involved in tissue regeneration (CTRs) that include maresin CTRs (MCTRs), protectin 
CTRs (PCTRs) and resolvin CTRs (RCTRs), which are biosynthesized from docosahexaenoic acid 
(DHA). The analytical approach consists of a gradient UPLC-MS/MS method for the analysis of pro-
inflammatory and pro-resolving GSH conjugates using positive electrospray ionization and collision-
induced fragmentation for identification and structural information, and a negative ionization mode 
for quantification. Several applications are highlighted in the publication.  Targeting esterified 
eicosanoids and other oxylipins, Schebb and Coworkers made a systematic evaluation of the 
influence of the method used for the extraction of lipids and the removal of proteins, the base 
hydrolysis conditions and the solid phase extraction approach on the precise and reproducible 
quantification of esterified oxylipins in plasma. The optimized methodology is of fundamental and 
practical use to all researchers interested in enhancing the sensitivity for quantification of oxygenated 
lipid mediators in biological systems. The optimized approach was demonstrated by measuring the 
changes in oxylipin pattern following omega-3 LCPUFA feeding in rats. The biological effect of 
these long chain polyunsaturated fatty acids (PUFA) being precursors of various lipid mediators are 
investigated in the last two papers of the special issue. LCPUFAs have been indicated to be protective 
in asthma, but it is unclear whether modulation of lung miRNA expression by LCPUFAs is involved. 
Fussbroich and colleagues found that for 62 miRNAs that were dysregulated significantly in mouse 
allergic asthma, LCPUFA supplementation restored 21 of them, relating to TGF-b signalling, 
extracellular matrix receptor interaction and fatty acid biosynthesis. This might be associated with 
LCPUFA reduction of COX2 and 5-LO activity. Güler, Schebb and colleagues describe the effects 
of dietary supplementation with both EPA and DHA on kidney tubular function in a murine model of 
acute kidney injury. Omega-3 LCPUFA -rich feeding for two weeks increased systemic and renal 
levels of omega-3 LCPUFA, as well as eicosanoids and other lipid mediators derived from omega-3 
LCPUFA, while omega-6 LCPUFA-derived mediators were decreased. Renal function impairment, 
renal damage and inflammation were not influenced, but tubular function was found to be protected, 
as shown by a higher expression of the  tubular transport marker alpha-1 microglobulin (A1M) in 
proximal tubular epithelial cells and upregulation of heme oxygenase-1 (HO-1). The results suggest 
that discrete functional adaptations take place that may protect kidney function in the face of acute 
kidney injury. 
 
The 7EWLM organizers would like to acknowledge the contributions of both the young as 
well as senior researchers that presented their work in Brussels.  We also thank the local staff at UCL 
Brussels led by Giulio Muccioli and Mireille Al Houayek who helped to organize the workshop 
logistics and made the event a wonderful experience for all participants. We would also like to 
sincerely acknowledge the generous sponsors of the 7th EWLM: Ambiotis, Antibodies-online, Avanti 
Polar Lipids, Bertin Pharma, Cayman, Genomics Online, Marine Ingredient KD Pharma, Lipidomix, 
Metagenics, ONO Pharmaceutical, Sanofi Aventis, VWR and Waters. Without their generous support 
this workshop would not have been possible. 
We are pleased to announce that the next edition of this workshop, 8EWLM, will be held at 
the Karolinska Institute in Stockholm June 24-26, 2020. The preliminary scientific program is 
attractive including a plenary lecture of Nobel laurate Bengt Samuelsson. For more information on 
our next event and to view the list of invited speakers, see our website: https://workshop-
lipid.eu/index.php?cat=Program. A special session for young researchers, and a session of 
educational presentations, will also be organized. 
 
Guest editors of this Special issue: 
Mireille Al Houayek  
Université Catholique de Louvain, Brussels  
Gerard Bannenberg 
GOED - Global Organization for EPA and DHA, Madrid, Spain 
Giulio G. Muccioli 
Université Catholique de Louvain, Brussels  
Xavier Norel 
INSERM U1148, Paris, France 
Chengcan Yao 
The University of Edinburgh 
Nils Helge Schebb 
University of Wuppertal, Germany 
